Gene · 23521
RPL13A: ribosomal protein L13a
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RPL13A: ribosomal protein L13a. Genes, record 23521. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/23521
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P40429 | Large ribosomal subunit protein uL13 | 203 | 177 | Ensembl, GeneID, HGNC |
Source UniProt
Patents39
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026504479 A | 2026-02-05 | 101 | P40429 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 5835 | P40429 | Espacenet |
| KR 1020250141243 A | 2025-09-26 | 101 | P40429 | Espacenet |
| EP 4514974 A2 | 2025-03-05 | 13 | P40429 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 5835 | P40429 | Espacenet |
| US 11564998 B2 | 2023-01-31 | 6764 | P40429 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 73942 | P40429 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 176913 | P40429 | Espacenet |
| WO 2020043864 A1 | 2020-03-05 | 2115 | P40429 | Espacenet |
| US 10463751 B2 | 2019-11-05 | 6764 | P40429 | Espacenet |
1 to 10 of 39
See all 39 patentsDrugs9
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ATALUREN | CHEMBL256997 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| CITATUZUMAB BOGATOX | CHEMBL1743000 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| CYCLOHEXIMIDE | CHEMBL123292 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| DORLIMOMAB ARITOX | CHEMBL2109124 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ELX-02 | CHEMBL4297744 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| MT-3724 | CHEMBL4297789 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TAPLITUMOMAB PAPTOX | CHEMBL2107890 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TELIMOMAB ARITOX | CHEMBL2108790 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ZOLIMOMAB ARITOX | CHEMBL2108785 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
Trials38
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07523581 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT05448755 | ELX-02 | PHASE2 | 2026-02-24 | ClinicalTrials.gov |
| NCT04336826 | ATALUREN | PHASE2 | 2024-04-01 | ClinicalTrials.gov |
| NCT04135495 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04126473 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04117880 | ATALUREN | PHASE2 | ClinicalTrials.gov | |
| NCT04069260 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04014530 | ATALUREN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT03796637 | ATALUREN | PHASE2 | 2022-04-05 | ClinicalTrials.gov |
| NCT03645395 | MT-3724 | PHASE2 | 2022-08-16 | ClinicalTrials.gov |
1 to 10 of 38
See all 38 trialsNIH grants2,185
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RPL13A papers | Newest fiscal year |
|---|---|---|---|
| P50CA097186 | The Pacific Northwest Prostate Cancer SPORE | 25 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 12 | 2025 |
| P01CA163227 | Androgen Receptor Action in Castration Resistant Prostate Cancer | 11 | 2025 |
| P30CA015704 | Cancer Center Support Grant | 9 | 2025 |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 9 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 8 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 7 | 2025 |
| P30DK048520 | Colorado Nutrition Obesity Research Center | 7 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 6 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 6 | 2025 |
1 to 10 of 2,185Source NIH's project files
See all 2,185 nih grantsPapers2,970
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Macrophage Differentiation Selectively Downregulates RPS15A While Preserving RPL13A and RPL17 Expression in THP-1-Derived Macrophages. | J Cardiovasc Dev Dis | 2026 | 42783057 | PubTator, text mining | PubMed |
| Reference Genes for Circadian Profiling of Core Clock Genes in the Blood of Obstructive Sleep Apnea Patients. | Biomolecules | 2026 | 42509806 | PubTator, text mining | PubMed |
| Determination of the most suitable reference gene for transcription analysis of synovial tissue from osteoarthritis patients. | Sci Rep | 2026 | 42469336 | PubTator, text mining | PubMed |
| Circulating mRNA and miRNA Signatures Used as Predictive Markers of Lifestyle Modification Outcomes in Pediatric Obesity Management. | Horm Res Paediatr | 2026 | 42391183 | PubTator, text mining | PubMed |
| Development and validation of a non-invasive RT-qPCR protocol for Nrf2 mRNA quantification in human tear fluid: A platform for ocular surface redox biomarker research. | Exp Eye Res | 2026 | 42248390 | PubTator, text mining | PubMed |
| METTL14-Mediated RPL13A Expression Regulates Apoptosis and Invasion of Osteosarcoma via the PTEN/PI3K/AKT Signaling Pathway. | J Orthop Res | 2026 | 42227596 | PubTator, text mining | PubMed |
| Validating the classics: Accurate reference gene panel for reliable RT-qPCR in Porifera. | PLoS One | 2026 | 42160319 | PubTator, text mining | PubMed |
| Gene Expression Alterations Associated With Resveratrol-Induced Antiproliferative Effects and S-Phase Cell Cycle Arrest in Osteosarcoma Cancer Cells. | J Cell Mol Med | 2026 | 41937498 | PubTator, text mining | PubMed |
| Development of a progressive HIV-1-Like infection model in northern pig-tailed macaques using stHIV-1sv/G53D. | Emerg Microbes Infect | 2026 | 41914615 | PubTator, text mining | PubMed |
| Redox cycling nitroxide limits cellular iron availability and selectively inhibits iron-sulfur cluster metabolism. | Cell Death Discov | 2026 | 41872136 | PubTator, text mining | PubMed |
1 to 10 of 2,970
See all 2,970 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/23521
GET https://conductscience.org/api/genes/v1/23521/patents?page=2